$AKESO(09926.HK), $3SBIO(01530.HK) have both risen by seven to eight percentage points, and $WUXI BIO(02269.HK), $WUXI APPTEC(02359.HK) have also followed higher, with Hong Kong-listed innovative drug stocks collectively rebounding in this wave. The adjustment to the Stock Connect Southbound list has included a batch of innovative drugs and CXO companies, coupled with the ongoing large license-out deals, mainland capital is chasing these stocks with relatively small free-floats. Once sector sentiment is ignited, innovative drugs and CXO move together, this wave looks more like a resonance between capital flows and fundamentals 😀
The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
